Literature DB >> 17117354

The science and practice of LSVT/LOUD: neural plasticity-principled approach to treating individuals with Parkinson disease and other neurological disorders.

Cynthia M Fox1, Lorraine O Ramig, Michelle R Ciucci, Shimon Sapir, David H McFarland, Becky G Farley.   

Abstract

Our 15 years of research have generated the first short- and long-term efficacy data for speech treatment (Lee Silverman Voice Treatment; LSVT/LOUD) in Parkinson's disease. We have learned that training the single motor control parameter amplitude (vocal loudness) and recalibration of self-perception of vocal loudness are fundamental elements underlying treatment success. This training requires intensive, high-effort exercise combined with a single, functionally relevant target (loudness) taught across simple to complex speech tasks. We have documented that training vocal loudness results in distributed effects of improved articulation, facial expression, and swallowing. Furthermore, positive effects of LSVT/LOUD have been documented in disorders other than Parkinson's disease (stroke, cerebral palsy). The purpose of this article is to elucidate the potential of a single target in treatment to encourage cross-system improvements across seemingly diverse motor systems and to discuss key elements in mode of delivery of treatment that are consistent with principles of neural plasticity.

Entities:  

Mesh:

Year:  2006        PMID: 17117354     DOI: 10.1055/s-2006-955118

Source DB:  PubMed          Journal:  Semin Speech Lang        ISSN: 0734-0478            Impact factor:   1.761


  42 in total

1.  Understanding the neural mechanisms involved in sensory control of voice production.

Authors:  Amy L Parkinson; Sabina G Flagmeier; Jordan L Manes; Charles R Larson; Bill Rogers; Donald A Robin
Journal:  Neuroimage       Date:  2012-03-03       Impact factor: 6.556

2.  Effect of level of presentation to listeners on scaled speech intelligibility of speakers with dysarthria.

Authors:  Yunjung Kim; Christina Kuo
Journal:  Folia Phoniatr Logop       Date:  2012       Impact factor: 0.849

3.  Physical exercise attenuates MPTP-induced deficits in mice.

Authors:  Trevor Archer; Anders Fredriksson
Journal:  Neurotox Res       Date:  2010-03-19       Impact factor: 3.911

4.  Delayed exercise-induced functional and neurochemical partial restoration following MPTP.

Authors:  Trevor Archer; Anders Fredriksson
Journal:  Neurotox Res       Date:  2011-08-10       Impact factor: 3.911

5.  Cross-activation and detraining effects of tongue exercise in aged rats.

Authors:  Allison J Schaser; Michelle R Ciucci; Nadine P Connor
Journal:  Behav Brain Res       Date:  2015-10-23       Impact factor: 3.332

6.  Exercise Effects on Early Vocal Ultrasonic Communication Dysfunction in a PINK1 Knockout Model of Parkinson's Disease.

Authors:  Cynthia A Kelm-Nelson; Katie M Yang; Michelle R Ciucci
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

7.  Decreased approach behavior and nucleus accumbens immediate early gene expression in response to Parkinsonian ultrasonic vocalizations in rats.

Authors:  Joshua D Pultorak; Cynthia A Kelm-Nelson; Lauren R Holt; Katherine V Blue; Michelle R Ciucci; Aaron M Johnson
Journal:  Soc Neurosci       Date:  2015-09-14       Impact factor: 2.083

8.  Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease.

Authors:  Giselle M Petzinger; Beth E Fisher; Sarah McEwen; Jeff A Beeler; John P Walsh; Michael W Jakowec
Journal:  Lancet Neurol       Date:  2013-07       Impact factor: 44.182

9.  Neural correlates of efficacy of voice therapy in Parkinson's disease identified by performance-correlation analysis.

Authors:  Shalini Narayana; Peter T Fox; Wei Zhang; Crystal Franklin; Donald A Robin; Deanie Vogel; Lorraine O Ramig
Journal:  Hum Brain Mapp       Date:  2010-02       Impact factor: 5.038

10.  Measures to Evaluate the Effects of DBS on Speech Production.

Authors:  Gary Weismer; Yana Yunusova; Kate Bunton
Journal:  J Neurolinguistics       Date:  2012-03       Impact factor: 1.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.